PRS15 A Cost-Utility Analysis of Dacomitinib As First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 21 L858R Substitution Mutation in China

Value in Health ◽

10.1016/j.jval.2021.04.1079 ◽

2021 ◽

Vol 24 ◽

pp. S215

Author(s):

G. Jin ◽

J. Zhao ◽

L. Luan ◽

P. Dong ◽

L. Yang

Keyword(s):

Locally Advanced ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Substitution Mutation ◽

First Line Treatment

Download Full-text

PCN53 Cost-Utility Analysis of Dacomitinib As First-LINE Treatment for Patients with Locally Advanced or Metastatic NON-SMALL CELL LUNG Cancer in China

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.103 ◽

2020 ◽

Vol 22 ◽

pp. S15

Author(s):

G. Jin ◽

J. Zhao ◽

L. Yang

Keyword(s):

Lung Cancer ◽

Locally Advanced ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

PCN40 Cost-Utility Analysis of Pembrolizumab Versus Platinum Based Chemotherapy As the First-LINE Treatment for Advanced and Metastatic NON-SMALL CELL LUNG Cancer (NSCLC) in UK

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.090 ◽

2020 ◽

Vol 22 ◽

pp. S12

Author(s):

J. Verma ◽

D. Verma ◽

A. Maria

Keyword(s):

Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

First Line Treatment

Download Full-text

Cost-Utility Analysis of Erlotib Versus Standard Chemotherapy in First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam

Value in Health ◽

10.1016/j.jval.2016.03.1614 ◽

2016 ◽

Vol 19 (3) ◽

pp. A154

Author(s):

TT Tran ◽

T Nguyen

Keyword(s):

Egfr Mutation ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Standard Chemotherapy ◽

First Line Treatment

Download Full-text

A Comparative Cost Utility Analysis For First Line Treatment Of Metastatic Non-Small Cell Lung Cancer (Nsclc) Patients With Egfr Exon 19 Deletions Or Exon 21 (L858r) Substitution Mutations

Value in Health ◽

10.1016/j.jval.2015.03.033 ◽

2015 ◽

Vol 18 (3) ◽

pp. A5-A6 ◽

Cited By ~ 1

Author(s):

J.J. Carlson ◽

J.F. Slejko ◽

H. Goertz ◽

D.L. Veenstra

Keyword(s):

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

Comparative Cost ◽

Substitution Mutations ◽

Nsclc Patients ◽

First Line Treatment

Download Full-text

Immunochemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non–Small Cell Lung Cancers

JAMA Oncology ◽

10.1001/jamaoncol.2021.3372 ◽

2021 ◽

Author(s):

Shujie Huang ◽

Zhen Gao ◽

Guibin Qiao

Keyword(s):

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Lung Cancers ◽

First Line Treatment

Download Full-text

EECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONTEXT

Value in Health ◽

10.1016/j.jval.2015.03.1179 ◽

2015 ◽

Vol 18 (3) ◽

pp. A307

Author(s):

J.L. Huicochea-Bartelt ◽

X. Burbano ◽

E. Palacios ◽

S. Herran ◽

C. Valencia

Keyword(s):

Locally Advanced ◽

Growth Factor Receptor ◽

Institutional Context ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

In response to She et al., “Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater”

Lung Cancer ◽

10.1016/j.lungcan.2020.06.014 ◽

2020 ◽

Vol 146 ◽

pp. 385-386

Author(s):

Min Huang ◽

Ralph P. Insinga ◽

Thomas Burke ◽

Ying Zhang ◽

Gilberto de Lima Lopes

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

A Cost-Utility Analysis of First-Line Treatment in Neuropathic Pain: Pregabalin Versus Venlafaxine

Value in Health ◽

10.1016/j.jval.2016.03.203 ◽

2016 ◽

Vol 19 (3) ◽

pp. A63

Author(s):

D Le ◽

A Born ◽

A Brinkerhoff ◽

V Vaidya

Keyword(s):

Neuropathic Pain ◽

Cost Utility ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

First Line ◽

First Line Treatment

Download Full-text

26 Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation

Lung Cancer ◽

10.1016/s0169-5002(13)70026-6 ◽

2013 ◽

Vol 79 ◽

pp. S9

Author(s):

R. Douglas ◽

L. Campbell ◽

J. McAleese ◽

P. Scullin

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Locally Advanced ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment

Download Full-text

Lacosamide As First Line Treatment Option In Focal Epilepsy; A Cost-Utility Analysis for The Greek Healthcare System

Value in Health ◽

10.1016/j.jval.2017.08.1953 ◽

2017 ◽

Vol 20 (9) ◽

pp. A724

Author(s):

M Geitona ◽

E Stamuli ◽

S Giannakodimos ◽

V Kimiskidis ◽

V Kountouris ◽

...

Keyword(s):

Healthcare System ◽

Treatment Option ◽

Focal Epilepsy ◽

Cost Utility ◽

Cost Utility Analysis ◽

Line Treatment ◽

Utility Analysis ◽

First Line ◽

First Line Treatment

Download Full-text